Andrew has represented clients the following matters:

• Investments in excess of $100 million by venture funds specializing in early-stage life science, information technology, and financing technology companies  
• Multiple emerging corporate clients (in the life sciences, ag-tech, information technology, and financial technology spaces) in raising in excess of $200 million of capital from venture capital funds, angel investors, angel investor networks, non-profit corporations, state agencies, and regional and national accelerators.
• An enzymes development company in a multiple million-dollar collaboration with a major agro-chemical company.
• Represented a software company in an exit transaction valued in excess of $30 million. 
• Multiple emerging life sciences companies with respect to university license agreements, research agreements, master services agreements, sponsored research agreements, material transfer agreements, confidentiality agreements, consulting agreements and other licenses and agreements. 
• An emerging medical diagnostics company in a capital raise in excess of $35 million.
• Represented buyers of early-stage technologies in distressed asset transactions.
• A consumer goods packaging company with the review, analysis, and negotiation of supply agreements and related commercial contracts.